1/10
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced |
---|
No study sessions yet.
EGFR Exon 19 deletion of exon 21 L858R substitution |
Osimertinib |
EGFR alterations (G719X, L861Q, S768I) |
Afatinib
EGFR Exon 20 insertion mutation |
Amivantamab-vmjw (Rybrevant) + carboplatin + pemetrexed |
ALK rearrangement |
Alectinib (Alecensa) Brigatinib (Alunbirg) Lorlatinib (Lorbrena) |
ROS1 |
Entretinib (Rozlytrek) Crizotinib (Xalkori) Reptotrectinib (Augtyro) |
BRAF point mutations |
Dabrafenib (Tafinlar) + Trametinib (Mekinist) Encorafenib (Braftovi) + Binimetinib (Mektovi) |
MET exon 14 (METex14) |
Capmatinib (Tabrecta) Tepotinib (Tepmetko) |
RET gene rearrangements |
Selpercatinib (Retevmo) Pralesetinib (Gavreto) |
KTRK fusion protein positive |
Larotectinib (Vitrakvi) Entrectinib (Rozlytrek) Repotrectinib (Augtyro) |
KRAS G12C inhibitor |
Sotorasib (Lumakras) Adagrasib (Krazati) |
HER2+ mutation |
FAM-trastuzumab deruxtecan (enhertu) Trastuzumab emtansine |